Dyadic International Inc. (NASDAQ:DYAI) Short Interest Down 26.4% in January

Dyadic International Inc. (NASDAQ:DYAI) saw a significant decrease in short interest in the month of January. As of January 15th, there was short interest totaling 147,183 shares, a decrease of 26.4% from the December 31st total of 200,065 shares. Based on an average daily trading volume, of 48,097 shares, the days-to-cover ratio is presently 3.1 days. Currently, 0.6% of the company’s shares are short sold. Currently, 0.6% of the company’s shares are short sold. Based on an average daily trading volume, of 48,097 shares, the days-to-cover ratio is presently 3.1 days.

Analysts Set New Price Targets

Several brokerages have issued reports on DYAI. Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research report on Monday, December 29th. HC Wainwright started coverage on Dyadic International in a research report on Thursday, October 23rd. They set a “buy” rating and a $3.00 target price for the company. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Dyadic International currently has a consensus rating of “Hold” and a consensus price target of $3.00.

Dyadic International Trading Down 1.3%

DYAI traded down $0.01 during trading on Tuesday, hitting $0.85. The company’s stock had a trading volume of 86,726 shares, compared to its average volume of 39,042. The firm has a market capitalization of $30.76 million, a P/E ratio of -3.54 and a beta of 1.27. Dyadic International has a twelve month low of $0.71 and a twelve month high of $1.73. The stock’s fifty day moving average price is $0.92 and its 200-day moving average price is $0.98. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 1.92.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The company had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.22 million. Dyadic International had a negative net margin of 221.09% and a negative return on equity of 537.31%. Analysts anticipate that Dyadic International will post -0.18 EPS for the current year.

Institutional Trading of Dyadic International

Several large investors have recently made changes to their positions in DYAI. Apis Capital Advisors LLC acquired a new position in Dyadic International during the 3rd quarter worth approximately $1,817,000. Chapin Davis Inc. increased its holdings in shares of Dyadic International by 5.6% during the third quarter. Chapin Davis Inc. now owns 932,004 shares of the biotechnology company’s stock valued at $1,100,000 after acquiring an additional 49,155 shares in the last quarter. Perkins Capital Management Inc. raised its position in shares of Dyadic International by 627.4% during the third quarter. Perkins Capital Management Inc. now owns 348,050 shares of the biotechnology company’s stock worth $411,000 after purchasing an additional 300,200 shares during the period. Truist Financial Corp lifted its holdings in shares of Dyadic International by 30.5% in the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock worth $385,000 after purchasing an additional 76,200 shares in the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new stake in Dyadic International in the 3rd quarter valued at $190,000. 27.95% of the stock is currently owned by institutional investors and hedge funds.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.